Ad
related to: gene therapy for genetic disorders journal impact factor- Discover Our Journals
More than 1.9 billion article views
Increase the impact of your work
- Become An Editor
Where scientists empower society
3rd most-cited publisher
- Join A Research Topic
Highly cited & widely read research
Achieve more views & downloads
- Submit Your Research
Journals led by external experts
Community-run publishing
- Discover Our Journals
Search results
Results from the WOW.Com Content Network
A more recent focus of the journal includes Cell Therapy, with genetic modification, in essence ex vivo gene therapy. Previous issues have focused on the latest developments in gene transfer, gene expression and regulation, development of novel gene delivery vectors, and ex vivo gene therapies, animal models, and human therapeutic applications.
The Journal of Gene Medicine is a monthly peer-reviewed medical journal covering gene therapy and other uses of genetic technologies for medical purposes. It was established in 1999 and is published by John Wiley & Sons. The editors-in-chief is Gening Jiang (Tongji University).
Gene therapy approaches to replace a faulty gene with a healthy gene have been proposed and are being studied for treating some genetic diseases. As of 2017, 11.1% of gene therapy clinical trials targeted monogenic diseases.
With the discovery of various types of immune-related disorders, there is a need for diversification in prevention and treatment. Developments in the field of gene therapy are being studied to be included in the scope of this treatment, but of course more research is needed to increase the positive results and minimize the negative effects of gene therapy applications. [27]
Gene is a peer-reviewed scientific journal in genetics and molecular biology, focusing on the cloning, structure, function, as well as the biomedical and biotechnological importance of genes. The scope of the journal includes all biological organisms including viruses, prokaryotes, and eukaryotes.
Genes & Diseases is a bimonthly peer-reviewed open access medical journal covering medical genetics. ... the journal has a 2020 impact factor of 7.103. [4] References
Cambiogenplasmid (Neovasculgen): treatment for vascular endothelial growth factor peripheral artery disease; Ciltacabtagene autoleucel (Carvykti): treatment for multiple myeloma [6] Delandistrogene moxeparvovec (Elevidys): treatment for Duchenne muscular dystrophy [7] [8] Elivaldogene autotemcel (Skysona): treatment for cerebral ...
As of 2021, Annual Review of Genomics and Human Genetics was published as open access, under the Subscribe to Open model. [1] [3] As of 2024, Journal Citation Reports lists the journal's impact factor as 7.7, ranking it thirteenth of 191 journal titles in the category "Genetics & Heredity". [2]
Ad
related to: gene therapy for genetic disorders journal impact factor